Determinants of variation in radical local treatment for men with high-risk localised or locally advanced prostate cancer in England
AuthorsParry, M. G.
Boyle, J. M.
van der Meulen, J.
Clarke, Noel W
AffiliationDepartment of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK.
MetadataShow full item record
AbstractBackground: Many factors are implicated in the potential 'under-treatment' of prostate cancer but little is known about the between-hospital variation. Methods: The National Prostate Cancer Audit (NPCA) database was used to identify high-risk localised or locally advanced prostate cancer patients in England, between January 2014 and December 2017, and the treatments received. Hospital-level variation in radical local treatment was explored visually using funnel plots. The intra-class correlation coefficient (ICC) quantified the between-hospital variation in a random-intercept multivariable logistic regression model. Results: 53,888 men, from 128 hospitals, were included and 35,034 (65.0%) received radical local treatment. The likelihood of receiving radical local treatment was increased in men who were younger (the strongest predictor), more affluent, those with fewer comorbidities, and in those with a non-Black ethnic background. There was more between-hospital variation (P < 0.001) for patients aged ≥80 years (ICC: 0.235) compared to patients aged 75-79 years (ICC: 0.070), 70-74 years (ICC: 0.041), and <70 years (ICC: 0.048). Comorbidity and socioeconomic deprivation did not influence the between-hospital variation. Conclusions: Radical local treatment of high-risk localised or locally advanced prostate cancer depended strongly on age and comorbidity, but also on socioeconomic deprivation and ethnicity, with the between-hospital variation being highest in older patients.
CitationParry MG, Boyle JM, Nossiter J, Morris M, Sujenthiran A, Berry B, et al. Determinants of variation in radical local treatment for men with high-risk localised or locally advanced prostate cancer in England. Prostate Cancer Prostatic Dis. 2021 Sep 7.
JournalProstate Cancer and Prostatic Diseases
- Determinants of Variation in the Use of Adjuvant Chemotherapy for Stage III Colon Cancer in England.
- Authors: Boyle JM, Kuryba A, Cowling TE, Aggarwal A, Hill J, van der Meulen J, Walker K, Braun MS
- Issue date: 2020 May
- Comparison of the treatment of men with prostate cancer between the US and England: an international population-based study.
- Authors: Parry MG, Nossiter J, Morris M, Sujenthiran A, Skolarus TA, Berry B, Nathan A, Cathcart P, Aggarwal A, van der Meulen J, Trinh QD, Payne H, Clarke NW
- Issue date: 2022 Jan 10
- Impact of cancer service centralisation on the radical treatment of men with high-risk and locally advanced prostate cancer: A national cross-sectional analysis in England.
- Authors: Parry MG, Sujenthiran A, Cowling TE, Nossiter J, Cathcart P, Clarke NW, Payne H, Aggarwal A, van der Meulen J
- Issue date: 2019 Jul 1
- The modern role of androgen deprivation therapy in the management of localised and locally advanced prostate cancer.
- Authors: Gunner C, Gulamhusein A, Rosario DJ
- Issue date: 2016 Dec
- Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.
- Authors: Moris L, Cumberbatch MG, Van den Broeck T, Gandaglia G, Fossati N, Kelly B, Pal R, Briers E, Cornford P, De Santis M, Fanti S, Gillessen S, Grummet JP, Henry AM, Lam TBL, Lardas M, Liew M, Mason MD, Omar MI, Rouvière O, Schoots IG, Tilki D, van den Bergh RCN, van Der Kwast TH, van Der Poel HG, Willemse PM, Yuan CY, Konety B, Dorff T, Jain S, Mottet N, Wiegel T
- Issue date: 2020 May